Lidocaine and Dexamethasone

Phase 2Small molecule

TThe University of Texas Medical Branch, Galveston

Lidocaine and Dexamethasone is one of 83 small molecule programs targeting Fibromyalgia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

FibromyalgiaActive, not recruiting

Subarachnoid HemorrhageActive, not recruiting

FibromyalgiaPhase 2/Phase 3

Active, not recruiting

Subarachnoid HemorrhagePhase 2

Active, not recruiting

Competition

Competitive Landscape

152 competitors in Fibromyalgia

#DrugCompanyPhaseTrials

Xyrem

Jazz Pharmaceuticals

Phase 3

1 2

Epidiolex

Jazz Pharmaceuticals

Phase 3

1 3

Namenda

AbbVie

Phase 3

1 4

Neurontin

VViatris Specialty LLC

Phase 3

3 5

Prozac

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

1 6

Ultram

WWim Janssens

Phase 3

1 7

DS-5565

Daiichi Sankyo

Phase 3

4 8

Feosol

AAuerbach Hematology Oncology Associates P C

Genotropin

Saizen

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Subarachnoid Hemorrhage

NCT07294118

Clinical

Trials by Indication[1]

Fibromyalgia1 trial

Ultrasound-Guided Stellate Ganglion Block in Fibromyalgia

Completed·—·Phase 2/3·NCT07343128·68 enrolled

Subarachnoid Hemorrhage1 trial

Infusion of Lidocaine and Steroids in Middle Meningeal Artery for Pain in Subarachnoid Hemorrhage

Recruiting·TThe University of Texas Medical Branch, Galveston·Phase 2·NCT07294118·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Lidocaine and Dexamethasone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lidocaine and Dexamethasone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lidocaine and Dexamethasone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The University of Texas Medical Branch, Galveston company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TThe University of Texas Medical Branch, Galveston

Lidocaine and Dexamethasone

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Fibromyalgia1 trial

Subarachnoid Hemorrhage1 trial

References

Drug Info

Quick Facts

Related News